Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.
Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
Like Elizabeth Holmes, Ramesh Balwani faces multiple counts of fraud related to the business practices of Theranos.
Aerium Therapeutics has officially launched following a successful Series A funding round led by seed investor Omega Funds.
In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.
Affini-T Therapeutics, a spin-out of the Fred Hutchinson Cancer Research Center, raised $175 million in initial financing. The company is focused on using T cells against mutations that drive cancer.
Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.